Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 8/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18428964 | 0.83 | L3MBTL1 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL27858121 | 0.83 | L3MBTL1 (0.34) | CHRM2CHRM1CHRM3L3MBTL1MEN1 | |
| SCHEMBL8701295 | 0.81 | L3MBTL1 (0.33) | L3MBTL1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL9579311 | 0.81 | CHRM1 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9547534 | 0.81 | L3MBTL1 (0.36) | L3MBTL1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL10653823 | 0.81 | L3MBTL1 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL28023530 | 0.80 | L3MBTL1 (0.32) | L3MBTL1MEN1KMT2ATDP1HTR1A | |
| SCHEMBL9936387 | 0.78 | L3MBTL1 (0.31) | L3MBTL1MEN1KMT2ATDP1HTR1A | |
| SCHEMBL5112834 | 0.78 | L3MBTL1 (0.31) | L3MBTL1MEN1KMT2ATDP1HTR1A | |
| SCHEMBL27651002 | 0.78 | MEN1 (0.32) | L3MBTL1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351545-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-07-16 | — | — | US | disclosed |
| US-10167272-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20180155315-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-20180022726-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9758506-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| US-20170037025-A1 | Muscarinic Agonists | NXERA PHARMA UK LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022726-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885CHRM4 4/4885CHRM5 5/4885 |
| US-10351545-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885CHRM4 4/4885CHRM5 5/4885 |
| US-20170037025-A1 | Muscarinic Agonists | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885CHRM4 4/4885CHRM5 5/4885 |
| US-20180155315-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885CHRM4 4/4885CHRM5 5/4885 |
| US-10167272-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885CHRM4 4/4885CHRM5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.